Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

861. Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations

exercise, lower fat diets, smoking cessation, and blood pressure assessment and control. There is insufficient evidence to make a recommendation on the use of HRT for the primary prevention of stroke and death from cerebrovascular disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cardiovascular Diseases /prevention & Cerebrovascular Disorders /prevention & Female; Hormone Replacement Therapy; Women's Health; control; control Language Published English Country (...) Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Postmenopausal hormone replacement therapy for the primary prevention of cardiovascular and cerebrovascular disease: systematic review and recommendations Abramson B L, with The Canadian

2003 Health Technology Assessment (HTA) Database.

862. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease

disease. Authors' conclusions For the combinations and conditions studied, the pooled analysis of smaller studies does not show evidence of an effect of vitamin E alone or in combination with other agents on all-cause mortality, cardiovascular mortality, fatal or nonfatal MI, or blood lipid levels. Results from a number of large clinical trials not included in the pooled analysis were substantially in agreement with this conclusion. Large studies of vitamin C in combination with other antioxidants (...) Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease Shekelle P, Morton S, Hardy M Record Status This is a bibliographic record of a published health

2003 Health Technology Assessment (HTA) Database.

863. Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders

Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Special report: Interventions to improve patient adherence with medications for chronic cardiovascular disorders. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(12). 2003 Authors

2003 Health Technology Assessment (HTA) Database.

864. Routine vitamin supplementation to prevent cardiovascular disease

Routine vitamin supplementation to prevent cardiovascular disease Routine vitamin supplementation to prevent cardiovascular disease Routine vitamin supplementation to prevent cardiovascular disease Morris C D, Carson S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Morris C D, Carson S. Routine vitamin supplementation to prevent (...) cardiovascular disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic Evidence Review. 2003 Authors' objectives This study aims to assess the evidence on the effectiveness of routine vitamin supplementation to prevent cardiovascular disease. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cardiovascular Diseases /prevention & Dietary Supplements; Vitamins; control Language Published English Country of organisation United States

2003 Health Technology Assessment (HTA) Database.

865. Biochemical markers of cardiovascular disease risk

and serves as a guide for statin therapy in a primary prevention context. C-reactive protein (CRP), if measured by high-sensitivity assay (hs-CRP), may have independent value as a predictor of cardiovascular disease risk and independent value in identifying patients with normal lipids who could benefit from treatment (Conclusion Grade II). hs-CRP elevations can be caused by inflammatory conditions and, therefore, are not specific for cardiovascular assessment in individual patients. Further study (...) Biochemical markers of cardiovascular disease risk Biochemical markers of cardiovascular disease risk Biochemical markers of cardiovascular disease risk Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institute for Clinical Systems Improvement. Biochemical markers of cardiovascular disease risk. Bloomington MN

2003 Health Technology Assessment (HTA) Database.

866. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

867. Effects of statins on nonlipid serum markers associated with cardiovascular disease

Effects of statins on nonlipid serum markers associated with cardiovascular disease Effects of statins on nonlipid serum markers associated with cardiovascular disease Effects of statins on nonlipid serum markers associated with cardiovascular disease Balk E M, Lau J, Goudas L C, Jordan H S, Kupelnick B, Kim L U, Karas R H CRD summary This review assessed the effects of statins on nonlipid serum markers associated with cardiovascular disease. Of the nonlipid serum markers examined, only levels (...) criteria for the participants were given, other than that those who had undergone organ transplantation were excluded. In the included placebo-controlled studies, most of the participants had hyperlipidaemia; some also had diabetes, cardiovascular disease, end-stage renal disease, or a recent myocardial infarction. Outcomes assessed in the review The outcomes were reported as class effect (i.e. effect of any statin), as well as the effects of particular statins and comparisons between statins. Studies

2003 DARE.

868. An update on aspirin in the primary prevention of cardiovascular disease

An update on aspirin in the primary prevention of cardiovascular disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 DARE.

869. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk

Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk (...) . Source of effectiveness data The effectiveness data were derived from a review of the literature. Modelling A model was constructed to combine the costs and effectiveness for each intervention. A standard multi-state modelling tool, PopMod, was used to translate changes in the risk of cardiovascular disease events, specific for age and gender, into changes in population health quantified by disability-adjusted life-years (DALYs). PopMod simulates the evolution, with and without each intervention

2003 NHS Economic Evaluation Database.

870. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy (...) for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Blake G J, Ridker P M, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This paper examined the use of screening for C-reactive protein

2003 NHS Economic Evaluation Database.

871. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease

compo- nent of the metabolic syndrome. 25 In several studies, base- line levels in the upper quartile of the population distri- bution in people without cardiovascular disease were associated with a 3- to 4-fold increased incidence of subse- quent coronary events. 24,26,27 Available data also suggest that measurement of the high-sensitivity C-reactive protein level may help target treatment to the population at risk; 28 this is relevant, since about half of all coronary events occur in people (...) , the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107(3):391-7. 26. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relationship of C-reactive pro- tein and coronary heart disease in the MRFIT nested case–control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144(6):537-47. 27. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C- reactive protein, a sensitive marker

2003 CPG Infobase

872. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. (Abstract)

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. The metabolic syndrome, a concurrence of disturbed glucose and insulin metabolism, overweight and abdominal fat distribution, mild dyslipidemia, and hypertension, is associated with subsequent development of type 2 diabetes mellitus and cardiovascular disease (CVD). Despite its high prevalence, little is known of the prospective association of the metabolic syndrome with cardiovascular and overall (...) mortality.To assess the association of the metabolic syndrome with cardiovascular and overall mortality using recently proposed definitions and factor analysis.The Kuopio Ischaemic Heart Disease Risk Factor Study, a population-based, prospective cohort study of 1209 Finnish men aged 42 to 60 years at baseline (1984-1989) who were initially without CVD, cancer, or diabetes. Follow-up continued through December 1998.Death due to coronary heart disease (CHD), CVD, and any cause among men with vs without

2002 JAMA

873. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. (Abstract)

Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. Recent appreciation of atherosclerosis as a chronic, inflammatory disease has rekindled efforts to examine the role that infectious agents may play in atherogenesis. In particular, much interest has focused on infection with Chlamydia pneumoniae. The possibility that a prokaryote contributes to atherogenesis has high clinical interest, as C pneumoniae infection may be a treatable risk factor. To review the evidence (...) in individuals with stable coronary artery disease. It is unlikely that C pneumoniae infection is necessary to initiate atherosclerosis. Furthermore, conventional antibiotic therapy may not eradicate the organism or reduce mortality in individuals with atherosclerotic vascular disease. Nevertheless, the current body of evidence establishes this pathogen as a plausible, potentially modifiable risk factor in cardiovascular disease.

2002 JAMA

874. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. Full Text available with Trip Pro

Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. To develop a model to determine resource costs and health benefits of implementing guidelines for the prevention of cardiovascular disease in primary care.Modelling of data from six strategies for prevention of cardiovascular disease. Strategies incorporated two ways of identifying patients for assessment: traditional (assessment of all (...) adults) and novel (preselection of patients for assessment using a prior estimate of their risk of cardiovascular disease). Three treatment strategies were modelled in conjunction with each identification strategy.England.Patients aged 30 to 74 eligible for primary prevention strategies for cardiovascular disease who were selected from a hypothetical population of 2000.Resource costs of assessing eligible adults, providing treatment and follow up to those eligible, and number of cardiovascular events

2002 BMJ

875. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. (Abstract)

Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. In cardiac syndrome X (a syndrome characterized by typical angina, abnormal exercise-test results, and normal coronary arteries), conventional investigations have not found that chest pain is due to myocardial ischemia. Magnetic resonance techniques have higher resolution and therefore may be more sensitive.We performed myocardial-perfusion cardiovascular magnetic resonance imaging (...) with syndrome X and 40 percent of controls (P<0.001).In patients with syndrome X, cardiovascular magnetic resonance imaging demonstrates subendocardial hypoperfusion during the intravenous administration of adenosine, which is associated with intense chest pain. These data support the notion that the chest pain may have an ischemic cause.

2002 NEJM

876. Psychological stress and cardiovascular disease: empirical demonstration of bias in a prospective observational study of Scottish men. Full Text available with Trip Pro

stress (fully adjusted odds ratio for incident angina, high versus low stress 2.66, 95% confidence interval 1.61 to 4.41; P for trend <0.001). Prevalence and incidence of ischaemia showed weak trends in the opposite direction. High stress was associated with a higher rate of admissions to hospital generally and for admissions related to cardiovascular disease and psychiatric disorders (fully adjusted rate ratios for any general hospital admission 1.13, 1.01 to 1.27, cardiovascular disease 1.20, 1.00 (...) to 1.45, and psychiatric disorders 2.34, 1.41 to 3.91). High stress was not associated with increased admission for coronary heart disease (1.00, 0.76-1.32) and showed an inverse relation with all cause mortality, mortality from cardiovascular disease, and mortality from coronary heart disease, that was attenuated by adjustment for occupational class (fully adjusted hazard ratio for all cause mortality 0.94, 0.81 to 1.11, cardiovascular mortality 0.91, 0.78 to 1.06, and mortality from coronary heart

2002 BMJ

877. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. (Abstract)

The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. The glycemic index was proposed in 1981 as an alternative system for classifying carbohydrate-containing food. Since then, several hundred scientific articles and numerous popular diet books have been published on the topic. However, the clinical significance of the glycemic index remains the subject of debate. The purpose of this review is to examine the physiological effects of the glycemic (...) index and the relevance of these effects in preventing and treating obesity, diabetes, and cardiovascular disease.

2002 JAMA

878. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). (Abstract)

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). The Heart and Estrogen/progestin Replacement Study (HERS) found no overall reduction in risk of coronary heart disease (CHD) events among postmenopausal women with CHD. However, in the hormone group, findings did suggest a higher risk of CHD events during the first year, and a decreased risk during years 3 to 5.To determine if the risk reduction observed (...) and CHD death. Secondary cardiovascular events were coronary revascularization, hospitalization for unstable angina or congestive heart failure, nonfatal ventricular arrhythmia, sudden death, stroke or transient ischemic attack, and peripheral arterial disease.There were no significant decreases in rates of primary CHD events or secondary cardiovascular events among women assigned to the hormone group compared with the placebo group in HERS, HERS II, or overall. The unadjusted relative hazard (RH

2002 JAMA Controlled trial quality: predicted high

879. Postmenopausal hormone replacement therapy and cardiovascular disease

Postmenopausal hormone replacement therapy and cardiovascular disease Postmenopausal hormone replacement therapy and cardiovascular disease Postmenopausal hormone replacement therapy and cardiovascular disease Humphrey LL, Takano LM, Chan BK Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humphrey LL, Takano LM, Chan BK. Postmenopausal (...) hormone replacement therapy and cardiovascular disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 10. 2002 Authors' objectives Cardiovascular disease (CVD) is the leading cause of death among women in the United States (US), and hormone replacement therapy (HRT) is commonly used, often for the prevention of CVD. The goal of this systematic evidence review and meta-analysis is to evaluate the association between HRT

2002 Health Technology Assessment (HTA) Database.

880. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. (Abstract)

Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. The relationship between sildenafil citrate use and reported adverse cardiovascular events in men with coronary artery disease (CAD) is unclear.To evaluate the cardiovascular effects of sildenafil during exercise in men with CAD.Randomized, double-blind, placebo-controlled crossover trial conducted March to October 2000 at a US ambulatory-care referral center

2002 JAMA Controlled trial quality: predicted high